Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer.

Autor:	Dobbs RW; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Hugar LA; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Revenig LM; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Al-Qassab S; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Petros JA; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Ritenour CW; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Issa MM; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA., Canter DJ; Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA.
Jazyk:	angličtina
Zdroj:	International braz j urol : official journal of the Brazilian Society of Urology [Int Braz J Urol] 2014 Mar-Apr; Vol. 40 (2), pp. 198-203.
DOI:	10.1590/S1677-5538.IBJU.2014.02.09
Abstrakt:	Purpose: The incidence of lower urinary tract symptoms (LUTS) as the sole presenting symptom for bladder cancer has traditionally been reported to be low. The objective of this study was to evaluate the prevalence and clinical characteristics of newly diagnosed bladder cancer patients who presented with LUTS in the absence of gross or microscopic hematuria. Materials and Methods: We queried our database of bladder cancer patients at the Atlanta Veteran's Affairs Medical Center (AVAMC) to identify patients who presented solely with LUTS and were subsequently diagnosed with bladder cancer. Demographic, clinical, and pathologic variables were examined. Results: 4.1% (14/340) of bladder cancer patients in our series presented solely with LUTS. Mean age and Charlson Co-morbidity Index of these patients was 66.4 years (range = 52-83) and 3 (range = 0-7), respectively. Of the 14 patients in our cohort presenting with LUTS, 9 (64.3%), 4 (28.6%), and 1 (7.1%) patients presented with clinical stage Ta, carcinoma in Situ (CIS), and T2 disease. At a median follow-up of 3.79 years, recurrence occurred in 7 (50.0%) patients with progression occurring in 1 (7.1%) patient. 11 (78.6%) patients were alive and currently disease free, and 3 (21.4%) patients had died, with only one (7.1%) death attributable to bladder cancer. Conclusions: Our database shows a 4.1% incidence of LUTS as the sole presenting symptom in patients with newly diagnosed bladder cancer. This study suggests that urologists should have a low threshold for evaluating patients with unexplained LUTS for underlying bladder cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu